Author index to volume 10

Aapro MS. *See* Gwyther SJ, 693
Abbruzzese JL. *See* Ravandi F, 519
Adachi Y. *See* Hashimoto Y, 323
Adam R. *See* Focan C, 385
Ahmed K. *See* Tomiyoshi K, 329
Aiba K. *See* Sato A, 741
Aita P. *See* Toffoli G, 511; *also* Corona G, 815
Akao S. *See* Ohno Y, 845
Akinaga S. *See* Akiyama T, 67
Akiyama T *et al.* Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B_1 regulation in A431 cells synchronized at M phase by nocodazole, 67
Akrivakis K *et al.* Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study, 525; *also* Schmid P, 625
Alessio E. *See* Sava G, 129
Allan WP. *See* Hasinoff BB, 47
Alyafei S. *See* Tomiyoshi K, 329
Alzieu C. *See* Gravis G, 369
Andreotti PE. *See* Cree IA, 437
Ang CY. *See* Swaffer DS, 113
Annemans L *et al.* The cost-effectiveness of paclitaxel (Taxol®)+cisplatin is similar to that of teniposide+cisplatin in advanced non-small cell lung cancer: a multicountry analysis, 605
Arakawa S. *See* Hara I, 711
Arning M. *See* Possinger K, 155; *also* Oettle H, 699
Ashizawa T *et al.* Antitumor activity of KF22678, a novel thioester derivative of leinamycin, 829
Ashkenazi YJ. *See* Wang Y, 797
Ashmore SM *et al.* Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma? 861
Atkins MB. *See* Hochster H, 245

Bacci G. *See* Ferrari S, 25
Bachrach U. *See* Wang Y, 797
Baiocchi M. *See* Corona G, 815
Bamberg M. *See* Weinmann M, 33
Bandak S *et al.* Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models, 911
Barret J-M *et al.* Novel artificial endonucleases inhibit base excision repair and potentiate the cytotoxicity of DNA-damaging agents on L1210 cells, 55; *also* Jean-Decoster C, 537
Barrows LR. *See* Matsumoto SS, 39; *also* Pond CD, 647
Bayssas M. *See* Newman RA, 889
Bearz A. *See* Corona G, 815
Bedikian AY *et al.* Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma, 735
Beijnen JH. *See* van Gijn R, 17; *also* Nuijen B, 870
Bencsik K. *See* Pályi I, 103
Bergman AM. *See* Padrón JM, 445
Bergmans M. *See* Wils J, 257
Berlion M. *See* Soudon J, 597
Bertola A. *See* Toffoli G, 511
Bigioni M. *See* Salvatore C, 663
Bismuth H. *See* Focan C, 385
Blay J-Y *et al.* Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens, 873
Bleuzen P. *See* Goldwasser F, 263
Blijham G. *See* Schmitt C, 617
Bódi J. *See* Botyánszki, 903
Böhm P. *See* Kollmannsberger C, 453
Boiocchi M. *See* Toffoli G, 511
Bokemeyer C. *See* Kollmannsberger C, 453; *See also* Hartmann JT, 729
Boldizsár M. *See* Pályi I, 103
Bonoron-Adèle S. *See* Platel D, 671
Boos J. *See* Würthwein G, 807
Bordukalo T. *See* Ozmak M, 853
Boschma F. *See* Wils J, 257
Botyánszki J *et al.* Synthesis and cytotoxic activity of *N*-(2-chloroethyl)-*N*-nitroureas and *N*-(2-chlorothyl)-*N*-nitrocarbamates, 903
Bouma M. *See* Nuijen B, 870
Bovenzi V *et al.* DNA methylation of retinoic acid receptor in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine, 471
Bozec L. *See* Goldwasser F, 195
Brandes A. *See* Weinmann M, 33
Brantis CE. *See* Perchellet EM, 749
Braud EL. *See* Ravandi F, 519
Brichese L. *See* Jean-Decoster C, 537
Bron H. *See* Wils J, 257
Brouwer E. *See* Loos WJ, 705
Brugger W. *See* Kollmannsberger C, 453
Bruno R. *See* Newman RA, 889
Bryce R. *See* Ilc K, 413
Budillon A *et al.* First international conference on new molecular targets for anticancer therapy, Naples, 22–23 June 1998, 249
Bult A. *See* Nuijen B, 870
Buthard X. *See* Goldwasser F, 263
Buzaid AC. *See* Bedikian AY, 735
Byttebier G. *See* Groener MGH, 283

Camerlo J. *See* Gravis G, 369
Caponigro F. *See* Budillon A, 249
Capozzi I. *See* Sava G, 129
Catimel G. *See* Schrijvers D, 633
Cerna C. *See* Soda H, 97; *also* Hidalgo M, 295, 837
Cesari M. *See* Ferrari S, 25
Chan H. *See* Lam W, 171
Chana J. *See* Cree IA, 437
Chandler LH. *See* Sparreboom A, 719
Chang H-K. *See* Liaw C-C, 275
Chang T-C *et al.* Phase II trial of neoadjuvant chemotherapy in early-stage small cell cervical cancer, 641
Chang W-C. *See* Chen J-S, 355
Chatterjee D. *See* Pantazis P, 317
Chazal M. *See* Chéradame S, 505
Chee G-L. *See* Hasinoff BB, 47
Chekhun VF. *See* Stoika RS, 457
Chen J-S *et al.* Weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced gastric cancer, 355; *also* Liaw C-C, 275
Chen S. *See* Mehta LK, 777
Chen Y. *See* Perchellet EM, 489
Chen Z. *See* Gu W-Z, 895
Cheng S. *See* Lam W, 171
Chéradame S *et al.* Variable intrinsic sensitivity of human tumor cell lines to raltitrexed (Tomudex®) and folylpolyglutamate synthetase activity, 505
Choi S *et al.* Single treatment with cisplatin or UFT, but not their combination treatment enhances the metastatic capacity of mouse fibrosarcoma cells, 235
Chou H-H. *See* Chang T-C, 641
Cianfriglia M. *See* Salvatore C, 663
Clark GM. *See* Genre D, 1; *also* Lawrence RA, 655
Claßen J. *See* Weinmann M, 33
Clerici K. *See* Sava G, 129
Cocchietto M. *See* Sava G, 129
Coleman R. *See* Possinger K, 155
Collery P. *See* Perchellet EM, 477

Colussi AM. *See* Toffoli G, 511; *also* Corona G, 815
Corona G *et al.* Pharmacokinetic interaction between etopside and tamoxifen in patients with hepatocellular carcinoma, 815; *also* Toffoli G, 511
Côté S. *See* Bovenzi V, 471
Cree IA *et al.* ATP-based tumor chemosensitivity testing: assisting new agent development, 431; *also.* Heterogeneity of chemosensitivity of metastatic cutaneous melanoma, 437
Cvitkovic E. *See* Goldwasser F, 263

Daikeler T. *See* Hartmann JT, 729
Dallaire BK. *See* Loos WJ, 705
Dallemagne B. *See* Focan C, 385
Darling JL. *See* Sankar A, 179; *also* Ashmore DGT, 861
de Boer-Dennert MM. *See* van Zuylen L, 361; *also* Planting AST, 821
De Bruijn E. *See* Schrijvers D, 633
de Bruijn P. *See* Mathijssen RHJ, 9; *See also* Sparreboom A, 719
De Bruyn E. *See* Schrijvers D, 147
de Graaff M *et al. In vitro* antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM, 213
De Jager RL. *See* Lawrence RA, 655
de Jonge MJA. *See* Mathijssen RHJ, 9; *also* Loos WJ, 705
de Pree N. *See* Wils J, 257
de Rooy C. *See* Wils J, 257
de Takats PG. *See* Cree IA, 437
Degen J. *See* Wils J, 257
Dempke W *et al.* Preferential repair of the N-*ras* gene in K 562 cells after exposure to cisplatin, 545
Deyama Y. *See* Sakakibara N, 203
Dhawan V *et al.* A unique paclitaxel-mediated modulation of the catalytic activity of topoisomerase IIα, 397
Diab SG *et al.* Significant activity of a novel cytotoxic agent, L Y295501, against a wide range of tumors in the human tumor cloning system, 303
Diebold T. *See* Oettle H, 699
Dietzmann A. *See* Genvesse I, 293
Dirix L. *See* Schrijvers D, 633
Dorr RT. *See* Mayr CA, 163
Droz JP. *See* Schrijvers D, 633
Duncan R. *See* Malik N, 767
Dwivedi C. *See* Singh BN, 139

Eckhardt SG. *also* Hidalgo M, 837
Edwards CL. *See* Verschraegen CF, 375
Edwards K. *See* Ravandi F, 519
Eksborg S. *See* Wang Y, 921
ElAttar TMA *et al.* Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation, 187
Endo K. *See* Higuchi T, 89; *also* Tomiyoshi K, 329
Erdkamp F. *See* Wils J, 257
Esposito M. *See* Viale M, 419
Etienne M-C. *See* Ilc K, 413
Étiévant C. *See* Barret J-M, 55
Eton O. *See* Bedikian AY, 735
Evagorou EG. *See* Malik N, 767

Fahy J. *See* Barret J-M, 55
Fasano MC. *See* Ferrari S, 25
Ferrari S *et al.* Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cislatin, methotrexate and standard-dose ifosfamide, 25
Ferrero JJ-M. *See* Ilc K, 413
Fischel J-L. *See* Ilc K, 413; *also* Chéradame S, 505; *also* Katona C, 561; *also* Soudon J, 597
Flath B. *See* Akrivakis K, 525; *also* Schmid P, 625
Floot BJG. *See* de Graaff M, 213
Focan C *et al.* Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion, 385
Focan-Henrard D. *See* Focan C, 385
Fong W. *See* Lam W, 171
Formento P. *See* Ilc K, 413; *also* Chéradame S, 505; *also* Soudon J, 597
Freedman RS. *See* Verschraegen CF, 375
Fujisawa S. *See* Tanaka M, 289
Fujita H. *See* Tanaka M, 289
Fujita M *et al.* Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines, 119
Fujiwara H. *See* Ohno Y, 845
Fujiwara T. *See* Ohno Y, 845
Fukuda K. *See* Ohno Y, 845
Fukuda H. *See* Sakakibara N, 203

Gabizon A. *See* Bandak S, 911
Gagliardi R. *See* Sava G, 129
Gelderblom HJ. *See* Loos WJ, 705
Genre D *et al.* Patients who are receiving concomitant medications should not systematically be excluded from phase I studies, 1
Genvresse I *et al.* Subacute encephalopathy after combination chemotherapy including moderate-dose methotrexate in a patient with gastric cancer, 293
Giaccone G. *See* Annemans L, 605
Giovanella BC. *See* Verschraegen CF, 375
Giroux B. *See* Soudon J, 597
Goey SH. *See* van Zuylen L, 361
Gohji K. *See* Hara I, 711
Goldwasser F *et al.* Cellular pharmacology of the combination of oxalipatin with topotecan in the IGROV-1 human ovarian cancer cell line, 195; *also* Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients, 263; *also* Gross M, 533
Gomez L. *See* Soda H, 97; *also* Hidalgo M, 295, 837
Gomi K. *See* Ashizawa T, 829
Goren D. *See* Bandak S, 911
Gotoh A. *See* Hara I, 711
Gotou K. *See* Ohno Y, 845
Grant J. *See* Cree IA, 437
Gravis G *et al.* Phase II study of a combination of low-dose cisplatin with 13-*cis*-retinoic acid and interferon-α in patients with advanced head and neck squamous cell carcinoma, 369
Griffin T. *See* Hidalgo M, 393
Groener MGH *et al.* An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer, 283
Gross M *et al.* Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, 533; *also* Goldwasser F, 263
Grosse Y. *See* Schmid P, 625
Grothey A. *See* Dempke W, 545
Gu W-Z *et al.* Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines, 895
Gupta E. *See* Verschraegen CF, 375
Gwyther SJ *et al.* Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer, 693

Hadelhah H. *See* Choi S, 235
Hadfield JA *et al.* Synthesis and anticancer activities of 4-oxobenxopyrano[2,3-*d*]pyridines, 591
Haest J. *See* Wils J, 257
Hall P. *See* Cree IA, 437

Han Z. *See* Pantazis P, 317
Hara I *et al.* Clinical outcome of high-dose chemotherapy combined with peripheral blood stem cell transplantation for male germ cell tumors, 711
Hara S. *See* Hara I, 711
Harper P. *See* Vincent M, 337
Harris JE. *See* Hochster H, 245
Harris N. *See* Verschraegen CF, 375
Hartmann JT *et al.* Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer, 729; *also* Kollmannsberger C, 453
Hartung G. *See* Stehle G, 405, 785
Hashimoto Y *et al.* Induction of apoptotic cell death in human hepatocellular carcinoma SK-HEP-1 cells by a polyamine synthesis inhibitor, methylglyoxal bis(cyclopentylamidinohydrazone), 323
Hasinoff BB *et al.* The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis, 47
Hatty SR. *See* Gwyther SJ, 693
Haughey HM. *See* Matsumoto SS, 39
Heene DL. *See* Stehle G, 405, 785
Helsing M. *See* Possinger K, 155
Henrar REC. *See* Nuijen B, 870
Hermans C. *See* Blay J-Y, 873
Hibasami H. *See* Hashimoto Y, 323
Hidalgo M *et al.* Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay, 295; *also* A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D_3) to prevent chemotherapy-induced alopecia, 393; *also* Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HM-AF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units, 837
Hiesse C. *See* Gross M, 533
Higashino K. *See* Fujita M, 119
Highley M. *See* Schrijvers D, 147; *also* Schrijvers D, 633
Higuchi T *et al.* Biodistribution and scintigraphy of [^{111}In]DTPA-adriamycin in mammary tumor-bearing rats, 89; *also* Tomiyoshi K, 329
Hill BT. *See* Barret J-M, 55; *also* Jean-Decoster C, 537; *also* van Hille B, 551
Hilsenbeck SG. *See* Diab SG, 303
Hobbs S. *See* Mehta LK, 777
Hochmuth K. *See* Oettle H, 699
Hochster H *et al.* Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687), 245
Holden JA. *See* Matsumoto SS, 39
Höppener FJP. *See* Schrijvers D, 633
Horowitz A. *See* Bandak S, 911
Horikoshi N. *See* Sato A, 741
Hosokawa M. *See* Choi S, 235; *also* Nakatsugawa S, 229
Houlbrook S. *See* Moody CJ, 577
Hsueh S. *See* Chang T-C, 641
Hua DH. *See* Perchellet EM, 489, 749
Hua J *et al.* Pharmacokinetics and central nervous system toxicity of declopramide (3-chloroprocainamide) in rats and mice, 79
Huang K-G. *See* Chang T-C, 641
Huang X. *See* Perchellet EM, 749
Huhn D. *See* Oettle H, 699
Hunt Strawderman M. *See* Hochster H, 245

Iafrate EM. *See* Salvatore C, 663
Iding R. *See* Wils J, 257
Ikoma J. *See* Hashimoto Y, 323
Ilc K *et al.* Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell lines, 413
Ilgan S. *See* Higuchi T, 89; *also* Zareneyrizi F, 685
Imoto I. *See* Hashimoto Y, 323
Inoue T. *See* Higuchi T, 89; *also* Tomiyoshi K, 329
Ireland CM. *See* Matsumoto SS, 39
Ishigaki T. *See* Nakatsugawa S, 229
Izbicka E. *See* Soda H, 97; *also* Hidalgo M, 295, 837; *also* Diab SG, 303; *also* Petit T, 309; *also* Lawrence RA, 655

Jasmin C. *See* Goldwasser F, 263; *also* Focan C, 385
Jausseran M. *See* Gravis G, 369
Jean-Decoster C *et al.* Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells, 537
Jehaes C. *See* Focan C, 385
Jeney A. *See* Katona C, 561
Jernej B. *See* Ozmak M, 853
Jewell RC. *See* Sparreboom A, 719
Jolain B. *See* Schmitt C, 617
Jubelirer SJ. *See* Hochster H, 245
Judson I. *See* Blay J-Y, 873
Jürgens H. *See* Würthwein G, 807

Kaito M. *See* Hashimoto Y, 323
Kálnay A. *See* Pályi I, 103
Kamei A. *See* Hashimoto Y, 323
Kamidono S. *See* Hara I, 711
Kanamori H. *See* Tanaka M, 289
Kane R. *See* Hua J, 79
Kaneta H. *See* Sakakibara N, 203
Kanda Y. *See* Ashizawa T, 829
Kanz L. *See* Kollmannsberger C, 453; *also* Hartmann JT, 729
Katona C *et al.* Modulation of 5-fluorouracil by 5-ethyl-2'-deoxyuridine on cell lines expressing different dihydroprimidine dehydrogenase activities, 561
Kaufmann M. *See* Possinger K, 155
Kavanagh JJ. *See* Verschraegen CF, 375
Kawashima K. *See* Ashizawa T, 829
Khoury GG. *See* Cree IA, 437
Kikkawa N. *See* Sato A, 741
Kim EE. *See* Higuchi T, 89; *also* Zareneyrizi F, 685
Kim JE. *See* Newman RA, 889
Kishimoto Y *et al.* A phase II study employing combination regimens containing KRN8602 in drug-resistant acute myeloid leukemia and acute lymphoblastic leukemia, 267
Klink-Alakl M. *See* Newman RA, 889
Knox RJ. *See* Mehta LK, 777
Kobayashi H. *See* Nakatsugawa S, 229; *also* Takemura Y, 677
Kobayashi M. *See* Choi S, 235
Koharazawa H. *See* Tanaka M, 289
Kollmannsberger C *et al.* Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma, 453; *also* Hartmann JT, 729
Konishi Y. *See* Choi S, 235
Kosmrlj J. *See* Ozmak M, 853
Koyama K. *See* Nakatsugawa S, 229
Kralovánszky J. *See* Katona C, 561
Kremmer T. *See* Pályi I, 103
Kreutz F. *See* Focan C, 385
Kriaa F. *See* Gross M, 533
Kruczynski A. *See* Jean-Decoster C, 537
Krümpelmann S. *See* Würthwein G, 807
Kudelka AP. *See* Verschraegen CF, 375
Kuraishi Y. *See* Kishimoto Y, 267
Kurbacher CM. *See* Cree IA, 431, 437
Kurihara M. *See* Sato A, 741

Labianca R. *See* Vincent M, 337
Ladesich JB. *See* Perchellet EM, 477, 489

Lai C-H. *See* Chang T-C, 641
Lalisang F. *See* Wils J, 257
Lam W *et al.* Synergism of energy starvation and dextran-conjugated doxorubicin in the killing of multidrug-resistant KB carcinoma cells, 171
Lamanna G. *See* Ferrari S, 25
Langrehr J. *See* Oettle H, 699
Lawrence R. *See* Soda H, 97
Lawrence RA *et al.* Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells, 655; *also* Petit T, 309
Lê NLO. *See* Bovenzi V, 471
Lee K-F. *See* Chang T-C, 641
Legha SS. *See* Bedikian AY, 735
Levi F. *See* Focan C, 385
Lewensohn R. *See* Wang Y, 921
Lhomme J. *See* Barret J-M, 55
Li X-G. *See* Pond CD, 647
Liau C-T. *See* Chen J-S, 355
Liaw C-C *et al.* Risk of transient hyperammonemic encephalopathy in cancer patients who recieved continuous infusion of 5-fluorouracil with the complication of dehydration and infection, 275
Liaw S-J. *See* Liaw C-C, 275
Liliemark E. *See* Wang Y, 921
Lin Y-C. *See* Liaw C-C, 275; *also* Chen J-S, 355
Lindberg A. *See* Wang Y, 921
Lindup WE. *See* Viale M, 419
Liu C-W. *See* Zareneyrizi F, 685
Liu H-E. *See* Chen J-S, 355
Lobelle JP. *See* Focan C, 385
Lockyer S. *See* Moody CJ, 577
Loos WJ *et al.* Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(*S*)-camptothecin in humans, 705; *also* Mathijssen RHJ, 9; *also* van Zuylen L, 361; *also* Sparreboom A, 719
Loyer E. *See* Verschraegen CF, 375
Luim D. *See* de Graaff M, 213

Ma J. *See* van Zuylen L, 361
MacDonald JR. *See* Hidalgo M, 837
MacKie RM. *See* Cree IA, 437
Magill MJ. *See* Perchellet EM, 489, 749
Maliepaard M. *See* de Graaff M, 213
Malik N *et al.* Dendrimer-platinate: a novel approach to cancer chemotherapy, 767
Manada C. *See* Nuijen B, 870
Manzini S. *See* Salvatore C, 663
Maraninchi D. *See* Gravis G, 369
Mariggiò MA. *See* Viale M, 419
Maruyama R. *See* Ohno Y, 845
Markiewicz S. *See* Focan C, 385
Masaoka T. *See* Kishimoto Y, 267
Massenkeil G. *See* Genvesse I, 293
Mathijssen RHJ *et al.* Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin, 9
Matsubara K. *See* Tomiyoshi K, 329
Matsumoto A. *See* Sakakibara N, 203
Matsumoto SS *et al.* Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction, 39
Matsuzaki M. *See* Tanaka M, 289
Maurer F. *See* Kollmannsberger C, 453
Mayer F. *See* Hartmann JT, 729
Mayr CA *et al.* Intracellular localization of 6- and 7-substituted 2-[2′-(dimethylamino-ethyl]-1,2-dihydro-3H-dibenz[*de,h*]isoquinoline-1,3-diones (azonafides) is not the limiting factor for their cytotoxicity; an *in vitro* confocal microscopy study, 163
McGowan AT. *See* Hadfield JA, 591
McIntyre S. *See* Bedikian AY, 735
Medina G. *See* Hidalgo M, 393
Mehta LK *et al.* Phthalimide analogs of CB 1954: synthesis and bioactivation, 777
Mergenthaler H-G. *See* Akrivakis K, 525; *also* Schmid P, 625
Mestroni G. *See* Sava G, 129
Mihalik R. *See* Pályi I, 103
Milano G. *See* Ilc K, 413; *also* Chéradame S, 505; *also* Katona C, 561; *also* Soudon J, 597
Mishima A. *See* Tanaka M, 289
Misset J-L. *See* Goldwasser F, 195; *also* Goldwasser F, 263; *also* Focan C, 385
Mitachi Y. *See* Sato A, 741
Miyachi H. *See* Takemura Y, 677
Miyake H. *See* Hara I, 711
Mizoguchi H. *See* Kishimoto Y, 267
Mohri H. *See* Tanaka M, 289
Momparler LG. *See* Bovenzi V, 471
Momparler RL. *See* Bovenzi V, 471
Moody CJ *et al.* Synthesis and cytotoxic activity of thiazolyl indolequinones, 577
Muramoto H. *See* Nakatsugawa S, 229
Murata T. *See* Tanaka M, 289
Myatt NE. *See* Cree IA, 437

Nakae D. *See* Choi S, 235
Nakamura I. *See* Hara I, 711
Nakashima K. *See* Hashimoto Y, 323
Nakatsugawa S *et al.* Inhibitory effect of ND2001 on spontaneous multiple metastasis of NC 65 tumors derived from human renal cancer cells intradermally transplanted into nude mice, 229
Nalin C. *See* Petit T, 309
Neale MH. *See* Cree IA, 437
Neuber K. *See* Cree IA, 437
Neuhaus P. *See* Oettle H, 699
Newman BM. *See* Newman RA, 889
Newman RA *et al.* Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors, 889
Ng S-C. *See* Gu W-Z, 895
Nomi M. *See* Hara I, 711
Nooter K. *See* Mathijssen RHJ, 9; *also* Sparreboom A, 719
Nuijen B *et al.* Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v administration, 879

Oettle H *et al.* Phase I trial of gemcitabine (Gemzar®), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer, 699
Ogawa M. *See* Kishimoto Y, 267
Oh C-S. *See* Zareneyrizi F, 685
Ohno Y *et al.* Induction of apoptosis by gallic acid in lung cancer cells, 845
Ohnmacht U. *See* Possinger K, 155
Oka Y. *See* Hara I, 711
Okabe K. *See* Kishimoto Y, 267
Okabe M. *See* Akiyama T, 67, 829
Okada F. *See* Choi S, 235
Oken M. *See* Hochster H, 245
Okuda T. *See* Nakatsugawa S, 229
Osmon C. *See* Ravandi F, 519
Oziel-Taieb S. *See* Gravis G, 369
Oznak M *et al.* Diazene JK-279: potential anticancer drug, 853

Padrón JM *et al.* Selective cell kill of the combination of gemcitabine and cisplatin in multilayered post-confluent tumor cell cultures, 445
Pályi I *et al.* Effects of methylacetylenic putrescine, an ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines, 103
Pandi E. *See* Katona C, 561
Pantazis P *et al.* Modulation of 9-nitrocamptothecin-induced apoptosis by hyperthermia in human leukemia HL-60 cells, 317
Papadopoulos N. *See* Bedikian AY, 735
Parkinson D. *See* Hochster H, 245
Parrick J. *See* Mehta LK, 777

Pastrone I. *See* Viale M, 419
Paul EM. *See* Sparreboom A, 719
Pavlidis VH. *See* Hadfield JA, 591
Pazdur R. *See* Ravandi F, 519; *also* Newman RA, 889
Pech-Gourgh F. *See* Gravis G, 369
Pelzer U. *See* Oettle H, 699
Perbellini A. *See* Sava G, 129
Perchellet EM *et al.* Microtubule-disrupting effects of gallium chloride *in vitro*, 477; *also* Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells *in vitro* and the growth of solid tumors *in vivo*, 489; *also* Triptycenes: a novel synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, induce DNA cleavage and decrease the viability of leukemic cells in the nanomolar range *in vitro*, 749
Perchellet J-P. *See* Perchellet EM, 477, 489, 749
Pero RW. *See* Hua J, 79
Perrin D. *See* van Hille B, 551
Perry PJ. *See* Hadfield JA, 591
Peters GJ. *See* Padrón JM, 445
Petit T *et al.* Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units, 309
Plager C. *See* Bedikian AY, 735
Planting AST *et al.* Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors, 821; *also* Sparreboom A, 719
Platel D *et al.* Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model, 671
Podoloff DA. *See* Higuchi T, 89; *also* Zareneyrizi F, 685
Polanc S. *See* Ozmak M, 853
Pond CD *et al.* Effects of mutations in the F361 to R364 region of topoisomerase I (Topo I), in the presence and absence of 9-aminocamptothecin, on the Topo I-DNA interaction, 647
Possinger K *et al.* Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer, 155; *also* Genvesse I, 293; *also* Akrivakis K, 525; *also* Schmid P, 625
Postmus PE. *See* Gwyther SJ, 693
Pouna P. *See* Platel D, 671
Pronk LC. *See* van Zuylen L, 361
Qing C. *See* Zhang X-W, 569
Quietzsch D. *See* Hartmann JT, 729
Ravandi F *et al.* Phase II trial of 5-fluorouracil, folinic acid and recombinant α-2-interferon in patients with advanced colorectal cancer, 519
Raymond E. *See* Soda H, 97
Real E. *See* Würthwein G, 807
Reinhold U. *See* Cree IA, 437
Remers WA. *See* Mayr CA, 163
Renée N. *See* Chéradame S, 505
Riesbeck K. Cisplatin at clinically relevant concentrations enhances interleukin-2 synthesis by human primary blood lymphocytes, 219
Riess H. *See* Oettle H, 699
Rinaldi D. *See* Hidalgo M, 393
Roach RW. *See* Ravandi F, 519
Robert J. *See* Platel D, 671
Robieux I. *See* Toffoli G, 511
Rodenhuis S. *See* van Gijn R, 17; *also* Blay J-Y, 873
Roffey JRA. *See* Moody CJ, 577
Romain D. *See* Goldwasser F, 263
Rosenberg SH. *See* Gu W-Z, 895
Rosing H. *See* van Gijn R, 17
Rougier P. *See* Schmitt C, 617
Rowinsky EK. *See* Hidalgo M, 295, 837; *also* Lawrence RA, 655
Rubin EH. *See* Pond CD, 647
Rutten FFH. *See* Groener MGH, 283
Rytting ME. *See* Ravandi F, 519
Saito H. *See* Kishimoto Y, 267
Sakakibara N *et al.* Inhibition of Na^+, K^+-ATPase by cisplatin and its recovery by 2-mercaptoethanol in human squamous cell carcinoma cells, 203
Sakata Y. *See* Sato A, 741
Salvatore C *et al.* FCE 24517-resistant MCF-7 human breast cancer cell line: selection and characterization, 663
Sami SM. *See* Mayr CA, 163
Sampi K. *See* Kishimoto Y, 267
Sankar A *et al.* Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide, 179
Sarosdy MF. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen, 791
Sartor G. *See* Corona G, 815
Sartori C. *See* Cree IA, 437
Sarwar M. *See* Tomiyoshi K, 329
Sato A *et al.* Phase II study of raltitrexed (Tomudex®) in chemotherapy-pretreated patients with advanced colorectal cancer, 741
Sava G *et al.* Reduction of lung metastasis by ImH[*trans*-$RuCl_4$(DMSO)Im]: mechanism of the selective action investigated on mouse tumors, 129
Schaub R. *See* Soda H, 97
Schellens JHM. *See* de Graaff M, 213; *also* van Zuylen L, 361; *also* Planting AST, 821
Schepers J. *See* Wils J, 257
Schmehl DM. *See* Matsumoto SS, 39
Schmid P *et al.* Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer, 625; *also* Akrivakis K, 525
Schmidt CA. *See* Oettle H, 699
Schmitt C *et al.* Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure, 617
Schmoll H-J. *See* Dempke W, 545
Schott U. *See* Weinmann M, 33
Schouten L. *See* Wils J, 257
Schrenk HH. *See* Stehle G, 405, 785
Schrijvers D *et al.* Role of red blood cells in pharmacokinetics of chemotherapeutic agents, 147; *also* KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study, 633
Schultze-Westhoff P. *See* Würthwein G, 807
Schweigert M. *See* Akrivakis K, 525
Sezer O. *See* Akrivakis K, 525; *also* Schmid P, 625
Sharma S. *See* Soda H, 97
Shimizu M. *See* Akiyama T, 67
Shirouzu K. *See* Sato A, 741
Singh BN *et al.* Antitumor drug delivery by tissue electroporation, 139
Sinn H. *See* Stehle G, 405, 785
Sinnett D. *See* Bovenzi V, 471
Skeel RT. *See* Hochster H, 245
Slaper-Cortenback ICM. *See* de Graaff M, 213
Smeets J. *See* Wils J, 257
Smith AE. *See* Gwyther SJ, 693
Smith M. *See* Blay J-Y, 873
Smith TAD. Hydroxyurea treatment enhances metastatic cell adhesiveness: a possible chemotherapy-induced increase in metastatic potential?, 429

Smitskamp-Wilms E. *See* Padrón JM, 445
Snijders M. *See* Wils J, 257
Soda H *et al.* Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors, 97
Soong Y-K. *See* Chang T-C, 641
Sorio R. *See* Toffoli G, 511; *also* Corona G, 815

Soudon J *et al.* Time-schedule dependency of S 16020, a new topoisomerase II inhibitor, 597
Sparreboom A *et al.* Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor or MDR1 P-gycoprotein, 719; *also* Mathjissen RHJ, 9; *also* Loos WJ, 705
Späth-Schwalbe E. *See* Genvesse I, 293
Steger M. *See* Verschraegen CF, 375
Stehle G *et al.* Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate, 785; *also* Methotrexate–albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats, 405
Stehlin JS. *See* Verschraegen CF, 375
Steltz V. *See* Verschraegen CF, 375
Stoika RS *et al.* Cisplatin-resistant derivatives of murine L1210 leukemia cells are not susceptible to growth-inhibiting and apoptosis-inducing actions of transforming growth factor-β1, 457
Stoot J. *See* Wils J, 257
Stoter G. *See* Mathjissen RHJ, 9; *also* van Zuylen L, 361; *also* Planting AST, 821
Stratford IJ. *See* Moody CJ, 577; *also* Botyánszki, 903
Stuart NSA. *See* Possinger K, 155
Süli-Vargha H. *See* Botyánszki, 903
Suzuki K. *See* Sakakibara N, 203
Swaffer DS *et al.* Growth inhibitory effect of L-canavanine against MIA PaCa-2 pancreatic cancer cells is not due to conversion to its toxic metabolite canaline, 113; *also* Dhawan V, 397
Swann E. *See* Moody CJ, 577

Tackechi Y. *See* Hara I, 711
Tahir SK. *See* Gu W-Z, 895
Takemoto Y. *See* Kishimoto Y, 267
Takemura G. *See* Ohno Y, 845
Takemura Y *et al.* Variable expression of the folylpolyglutamate synthetase gene at the level of mRNA transcription in human leukemia cell lines sensitive, or made resistant, to various antifolate drugs, 677
Tamaki S. *See* Hashimoto Y, 323
Tamaoki T. *See* Akiyama T, 67; *also* Ashizawa T, 829
Tamura K. *See* Kishimoto Y, 267
Tanaka M *et al.* Low-dose cytarabine-induced hepatic and renal dysfunction in a patient with myelodysplastic syndrome, 289
Tansey LW. *See* Higuchi T, 89
Tansey W. *See* Zareneyrizi F, 685
ten Bokkel Huinink WW. *See* van Gijn R, 17
Thampatty P. *See* Hasinoff BB, 47
Thomas DGT. *See* Sankar A, 179; *also* Ashmore DGT, 861
Tillman B. *See* Würthwein G, 807
Timár F. *See* Katona C, 561
Toffoli G *et al.* Effect of cyclosporin A on protein binding of teniposide in cancer patients, 511; *also* Corona G, 815
Tohgo A. *See* Lawrence RA, 655
Tollon Y. *See* Jean-Decoster C, 537
Tomiyoshi K *et al.* Metabolic studies of [^{18}α-methyl]tyrosine in mice bearing colorectal carcinoma LS-180, 329
'Tomudex' Cooperative Study Group, 741
Totsuka Y. *See* Choi S, 235
Toyota M. *See* Ohno Y, 845
Tseng C-J. *See* Chang T-C, 641
Tsuchida T. *See* Fujita M, 119
Tsuruoka T. *See* Nakatsugawa S, 229
Turi G. *See* Pályi I, 103
Turner J. *See* Hidalgo M, 393
Tzemach D. *See* Bandak S, 911

Ueda K. *See* Ashizawa T, 829

van Alphen RJ. *See* Mathjissen RHJ, 9
Van Custsem E. *See* Schmitt C, 617
van der Burg MEL. *See* Sparreboom A, 719; *also* Planting AST, 821
van der Gaast A. *See* Sparreboom A, 719
van der Wilt CL. *See* Padrón JM, 445
van Erp J. *See* Wils J, 257
van Glabbeke M. *See* Blay J-Y, 873
van Geuns H. *See* Wils J, 257
van Gijn R *et al.* Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study, 17
van Hille B *et al.* Differential *in vitro* interactions of clinically useful topoisomerase-interacting compounds with the cleavage/religation activity of the human topoisomerase IIα and IIβ isoforms, 551
van Hout. *See* Groener MGH, 283
van Ineveld BM. *See* Groener MGH, 283
van Moorsel CJA. *See* Padrón JM, 445
Van Oosterom AT. *See* Schrijvers D, 147, 633
van Tellingen O. *See* van Gijn R, 17
van Warmerdam LJC. *See* van Gijn R, 17
van Zuylen L *et al.* Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer, 361
Venables DA. *See* Matsumoto SS, 39
Vergenègre A. *See* Annemans L, 605
Vermorken JB. *See* van Gijn R, 17; *also* Schrijvers D, 147
Vernillet L. *See* Mathjissen RHJ, 9
Verschraegen CF *et al.* A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer, 375
Verweij J. *See* Mathjissen RHJ, 9; *also* van Zuylen L, 361; *also* Loos WJ, 705; *also* Sparreboom A, 719; *also* Planting AST, 821; *also* Blay J-Y, 873
Viale M *et al.* Cisplatin combined with tiopronin or sodium thiosulfate: cytotoxicity *in vitro* and antitumor activity *in vivo*, 419
Viallet J. *See* Bedikian AY, 735
Viens P. *See* Genre D, 1; *also* Gravis G, 369
Vincent M *et al.* Which 5-fluorouracil regimen? The great debate, 337
Virji AS. *See* ElAttar TMA, 187
Vogl TJ. *See* Oettle H, 699
Voigt W. *See* Dempke W, 545
Voinea A. *See* Goldwasser F, 263
Von Hoff DD. *See* Genre D, 1; *also* Soda H, 97; *also* Hidalgo M, 295, 393, 837; *also* Diab SG, 303; *also* Petit T, 309; *also* Lawrence RA, 655
Vreeswijk J. *See* Wils J, 257

Wakui Y. *See* Sato A, 741
Wals J. *See* Wils J, 257
Wang C-H. *See* Liaw C-C, 275; *also* Chen J-S, 355
Wang H-M. *See* Liaw C-C, 275; *also* Chen J-S, 355
Wang Y *et al. In vitro* chemosensitivity testing of hematological cancers: immunohistochemical detection of ornithine decarboxylase, 797; *also In vitro* cellular accumulation and cytoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells, 921

Watanabe M. *See* Ohno Y, 845
Watanabe S. *See* Hashimoto Y, 323
Weaver PC. *See* Cree IA, 437
Weerts J. *See* Focan C, 385
Weinmann M *et al.* Impressive remission in a patient with locally advanced malignant pleural mesothelioma treated with gemcitabine, 33
Weitman SD. *See* Hidalgo M, 295, 837; *also* Diab SG, 303; *also* Petit T, 309; *also* Lawrence RA, 655
Werter M. *See* Wils J, 257
Wetzels L. *See* Wils J, 257
Wils J *et al.* Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic–IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Lmburg, 257
Winn R. *See* Ravandi F, 519
Winograd B. *also* Planting AST, 821
Wissel PS. *See* Sparreboom A, 719
Wright M. *See* Jean-Decoster C, 537
Wunder A. *See* Stehle G, 405, 785
Würthwein G *et al.* Population pharmacokinetic approach to compare oral and i.v. administration of etopside, 807
Wyche J. *See* Pantazis P, 317

Xinbin Q. *See* Ohno Y, 845
Xu B. *See* Zhang X-W, 569

Yakymovych IA. *See* Stoika RS, 457
Yakymovych MYa. *See* Stoika RS, 457
Yalowich JC. *See* Hasinoff BB, 47
Yamada Y. *See* Hara I, 711
Yamaji S. *See* Tanaka M, 289
Yamanaka K. *See* Hara I, 711
Yang D. *See* Tomiyoshi K, 329
Yang DJ, *See* Higuchi T, 89; *also* Zareneyrizi F, 685
Yang M. *See* Lam W, 171
Yang T-S. *See* Liaw C-C, 275; *also* Chen J-S, 355
Yasuda N. *See* Ohno Y, 845
Yeh C-T. *See* Liaw C-C, 275
Yoshimura Y. *See* Sakakibara N, 203
Yu D-F. *See* Zareneyrizi F, 685

Zareneyrizi F *et al.* Synthesis of [^{99m}Tc]ethylenedicysteine-colchicine for evaluation of antiangiogenic effect, 685; *also* Higuchi T, 89
Zeghari-Squalli N. *See* Goldwasser F, 195
Zhang H. *See* Tomiyoshi K, 329
Zhang J-G. *See* Viale M, 419
Zhang X-W *et al.* Apoptosis induction and cell cycle perturbation in human Hep G2 cells by 10-hydroxycamptothecin, 569
Zolezzi C. *See* Ferrari S, 25